The BRU will support the development of biomarkers of LBD which is extremely important and very challenging, due to the complex nature of the disease producing high levels of disability due to a combination of motor and non-motor symptoms.
Not only are biomarkers likely to play an increasing role in terms of diagnostic and prognostic assessments, but also they will be vital for the early assessment and monitoring of efficacy of novel interventions. Supporting the main clinical disease theme our research will identify and validate new biomarkers which will be utilised in clinical practice.